Literature DB >> 10906221

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

J C Ramírez1, M M Gherardi, D Rodríguez, M Esteban.   

Abstract

A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and beta-galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10906221      PMCID： PMC112288          DOI： 10.1128/jvi.74.16.7651-7655.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.

Authors:  T Takeshita; H Takahashi; S Kozlowski; J D Ahlers; C D Pendleton; R L Moore; Y Nakagawa; K Yokomuro; B S Fox; D H Margulies
Journal:  J Immunol       Date:  1995-02-15       Impact factor: 5.422

Review 2.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

Review 4.  Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

Authors:  B Moss; M W Carroll; L S Wyatt; J R Bennink; V M Hirsch; S Goldstein; W R Elkins; T R Fuerst; J D Lifson; M Piatak; N P Restifo; W Overwijk; R Chamberlain; S A Rosenberg; G Sutter
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

5.  Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.

Authors:  H M Etlinger; W Altenburger
Journal:  Vaccine       Date:  1991-07       Impact factor: 3.641

6.  Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen.

Authors:  C Flexner; B R Murphy; J F Rooney; C Wohlenberg; V Yuferov; A L Notkins; B Moss
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

7.  Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans.

Authors:  A L Erickson; C M Walker
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

8.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.

Authors:  T M Kündig; C P Kalberer; H Hengartner; R M Zinkernagel
Journal:  Vaccine       Date:  1993       Impact factor: 3.641
View more
  33 in total

Review 1.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

2.  Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.

Authors:  Michael Walther; Fiona M Thompson; Susanna Dunachie; Sheila Keating; Stephen Todryk; Tamara Berthoud; Laura Andrews; Rikke F Andersen; Anne Moore; Sarah C Gilbert; Ian Poulton; Filip Dubovsky; Eveline Tierney; Simon Correa; Angela Huntcooke; Geoffrey Butcher; Jack Williams; Robert E Sinden; Adrian V S Hill
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Authors:  Lorena F D de Freitas; Rafael P Oliveira; Mariana C G Miranda; Raíssa P Rocha; Edel F Barbosa-Stancioli; Ana Maria C Faria; Flávio G da Fonseca
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Authors:  Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong Y Tsang
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

5.  Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.

Authors:  Laurie E Harrington; Robbert van der Most Rv; J Lindsay Whitton; Rafi Ahmed
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Authors:  Annett Hessel; Michael Schwendinger; Daniela Fritz; Sogue Coulibaly; Georg W Holzer; Nicolas Sabarth; Otfried Kistner; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

7.  Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Authors:  Josef Mayrhofer; Sogue Coulibaly; Annett Hessel; Georg W Holzer; Michael Schwendinger; Peter Brühl; Marijan Gerencer; Brian A Crowe; Shen Shuo; Wanjing Hong; Yee Joo Tan; Barbara Dietrich; Nicolas Sabarth; Helga Savidis-Dacho; Otfried Kistner; P Noel Barrett; Falko G Falkner
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

8.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2013-02-01       Impact factor: 3.641

10.  MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

Authors:  Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; Geert van Amerongen; Astrid Schwantes; Judith M A van den Brand; Ron A M Fouchier; Johannes Löwer; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.